Sound Pharmaceuticals
Client: Sound Pharmaceuticals
Sector: Biopharmaceutical
Transaction: Principal Investment
Sound Pharmaceuticals is a Seattle-area biopharmaceutical company focused on developing drugs to prevent and treat various forms of hearing loss. According to the company, roughly 30 million to 40 million Americans suffer from this condition, but there are currently no FDA-approved pharmaceutical therapies. The company recently announced that its lead product, SPI-1005, has entered Phase 2 clinical trials. Broadmark has served as an informal advisor to the company's management team; our primarly role has been as an active investor.